145 related articles for article (PubMed ID: 9085628)
1. Hepatotoxicity after a short course of low-dose pyrazinamide.
al Sarraf KA; Michielsen PP; Hauben EI; Lefebure A; Ramon AM; Van Marck EA; Pelckmans PA
Acta Gastroenterol Belg; 1996; 59(4):251-3. PubMed ID: 9085628
[TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
3. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
4. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Cook PP; Maldonado RA; Yarnell CT; Holbert D
Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
[TBL] [Abstract][Full Text] [Related]
5. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
[No Abstract] [Full Text] [Related]
6. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
Singh J; Garg PK; Thakur VS; Tandon RK
Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
[TBL] [Abstract][Full Text] [Related]
7. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Ijaz K; McElroy PD; Navin TR
Clin Infect Dis; 2004 Jul; 39(2):289. PubMed ID: 15307044
[No Abstract] [Full Text] [Related]
8. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
Burman WJ; Reves RR
Am J Respir Crit Care Med; 2001 Oct; 164(7):1112-3. PubMed ID: 11673194
[No Abstract] [Full Text] [Related]
9. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
10. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
[TBL] [Abstract][Full Text] [Related]
11. [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Camacho A; Pérez-Camacho I; Rivero A; Natera C; García-Lázaro M; Castón JJ; Gallo M; Kindelán JM; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):239-44. PubMed ID: 19647900
[TBL] [Abstract][Full Text] [Related]
12. [Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin].
Slivka IuI; Klimniuk EV; Tabachuk OE
Probl Tuberk; 1989; (4):39-42. PubMed ID: 2734263
[TBL] [Abstract][Full Text] [Related]
13. Pyrazinamide-induced sideroblastic anemia.
Colucci G; Silzle T; Solenthaler M
Am J Hematol; 2012 Mar; 87(3):305. PubMed ID: 21818765
[No Abstract] [Full Text] [Related]
14. [Isoniazid-induced hepatic failure. Report of a case].
Pereira RM; Tresoldi AT; Hessel G
Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
[TBL] [Abstract][Full Text] [Related]
15. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
[TBL] [Abstract][Full Text] [Related]
17. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
18. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
20. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Chang KC; Leung CC
Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
[No Abstract] [Full Text] [Related]
[Next] [New Search]